Introduction
Cardiac gene transfer has been considered as a promising therapeutic tool in cardiology. Although our knowledge in molecular mechanisms of cardiac diseases has grown exponentially, development of efficient and feasible gene transfer has not been able to match that pace. Several clinical trials related to cardiac gene therapy were not able to meet expectations, mostly lacking relevant clinical and physiological efficacy. 1, 2 In addition to suitable candidate genes, vector design, vector type and mode of vector delivery will influence success in cardiac gene therapy.
Most delivery systems have been based upon invasive procedures, such as direct intramyocardial injection [3] [4] [5] [6] [7] [8] and prolonged or enhanced coronary perfusion. [9] [10] [11] [12] [13] [14] [15] However, these techniques have inherent risks that may outweigh their benefit. Therefore, the development of noninvasive but highly organ-specific systemic gene transfer approaches has been a major focus.
Presently, one of the most promising vector systems for noninvasive cardiac gene transfer is the adenoassociated virus (AAV), a nonpathogenic parvovirus.
In comparison with naked DNA and adenoviral vectors (the two most commonly used vectors in cardiac gene transfer), AAV has the advantage of being suitable for long-term gene transfer into the myocardium, demonstrating gene expression for at least 1 year. 5, 16 AAV serotype 2 vectors have been most intensively studied and have been successfully used in several experimental therapeutic approaches such as protection from ischemia/reperfusion injury in a rat model 17 or gene replacement therapy in cardiomyopathic hamsters 18, 19 and revealed beneficial effects on neoangiogenesis, infarct size and cardiac function in a murine model of myocardial ischemia. 20 However, to achieve highly selective transduction of myocardial tissue, AAV vectors were administered by intramyocardial injection or selective perfusion of coronary arteries. With identification of more AAV serotypes, the natural diversity of AAV capsids was utilized in terms of tissue-tropism and transduction efficiency by generation of pseudotyped vectors. 21 In comparison to AAV-2, AAV-6-pseudotyped vectors lead to higher myocardial transduction after intramyocardial injection and systemic administration. [22] [23] [24] [25] Other AAV serotype vectors such as AAV-8 or -9 resulted in even higher cardiac transduction levels after intravenous injection in adult mice. [26] [27] [28] Specificity and efficiency of myocardial gene transfer with pseudotyped AAV vectors could be further increased using the 1.5 kb myosin light chain-2v promoter fused to a cytomegalovirus (CMV) enhancer. 25 However, the use of pseudotyped and transcriptionally targeted AAV vectors for systemic application in larger animals is still limited by the high amount of vector necessary for efficient transduction and gene expression, even if celltype-specific promoters are used. Therefore, a mechanical but noninvasive targeting of AAV vectors would be advantageous.
These aspects could be combined by a technique that has evolved as a new site-specific targeting tool in gene and drug delivery: ultrasound-targeted microbubble destruction (UTMD). It is based upon gas-filled microbubbles that are used as ultrasound contrast agents. When sonified with ultrasound in their resonance frequency (between 1 and 2 MHz), high mechanical index ultrasound will induce high amplitude oscillations that lead to microbubble destruction. Although this phenomenon can be used to characterize refill kinetics of tissue perfusion, 29 it can also be used to deliver a microbubble-loaded bioactive substance into an organ. 30, 31 In addition, UTMD benefits from secondary effects of microbubble destruction that will increase capillary permeability and produce transient nanopores in cell membranes by developing high velocity fluid microjets in their near vicinity. 32 On the basis of these phenomena, both adenoviral vectors 33 and plasmid DNA [34] [35] [36] were successfully delivered to the heart. Therefore, the aim of this study was to investigate whether UTMD could augment AAV-mediated gene transfer to the heart. We tested if systemic administration of AAV-6 or AAV-9-pseudotyped vectors in low doses (as used for mice) could lead to more efficient gene expression in rats when using UTMD. Furthermore, we investigated whether UTMD-enhanced AAV delivery to the myocardium increases organ specificity, and whether it causes relevant adverse effects.
Results

Microbubbles and immunostaining
Mean microbubble count for virus-loaded microbubbles was 1. 41 ± 0.3 Â 10 9 per ml and mean microbubble size was 2.19±2.0 mm. For unloaded microbubbles mean count was 1.39 ± 0.2 Â 10 9 per ml and mean microbubble size was 2.01±1.9 mm. Thus, AAV loading did not influence microbubble characteristics.
To prove AAV binding, immunostaining of loaded and unloaded microbubbles was performed, taking advantage of the anionic microbubble surface and cationic AAV capsids. Initial mean microbubble count in this experiment was 5.68 ± 0.2 Â 10 7 , resulting in a virus/microbubble ratio of approximately 1000:1. After all washing steps, 30% of the original microbubbles could be retrieved, due to low stability of microbubbles when exposed to repetitive flotation, gentle shaking and decantation.
Although specific staining was absent on control microbubbles without AAV (Figure 1b) , AAV-loaded microbubbles revealed a strong fluorescence signal on the microbubble surface (Figure 1a ), demonstrating that AAV was indeed bound on the microbubble surface.
In vivo gene transfer
The influence of UTMD on transduction efficiency of different AAV serotypes was investigated separately for AAV-6 and -9 serotypes harboring a luciferase reporter gene.
In AAV-6-treated rats, left ventricles demonstrated a significantly higher transgene expression (sixfold) in the UTMD group, compared to the control group receiving AAV without microbubbles in the presence of ultrasound (151705 ± 76783 vs 24563 ± 24751, Po0.05; Figure 2a ). For the right ventricle, UTMD resulted in a trend toward higher reporter activities (fivefold; 101903 ± 78558 vs 18805±24135, P ¼ 0.21) with a similar result in atria (threefold; 4681 ± 3897 vs 1406 ± 3146, P ¼ 0.18). Expression in other organs was close to background except for the liver, which revealed significant luciferase activities in both groups most probably due to high tropism of AAV-6 vectors for rat liver.
As with AAV-6, AAV-9-pseudotyped vectors loaded on microbubbles resulted in significantly higher transduction levels in left ventricular myocardium (23-fold) compared to AAV-9 without microbubbles (326427±198012 vs 13900±15094, Po0.05; Figure 2b ). Although not significant, there was a trend toward higher reporter gene activities in right ventricle (sevenfold; 52476 ± 42194 vs 7683 ± 4570, P ¼ 0.12), atrium (twofold; 18328±21351 vs 9070±13281, P ¼ 0.49) and liver (fourfold; 49742 ± 33213 vs 11543 ± 16487, P ¼ 0.10) with the AAV-9/microbubble mixture compared to controls.
To analyze whether the increased luciferase activities in the UTMD group are reflected by an increased vector uptake, we quantified vector genomes in heart and liver by TaqMan real-time PCR upon transfer of AAV-6 vectors with and without microbubbles in the presence of ultrasound ( Figure 3 ). Although not significant, UTMD resulted in increased copies of vector genomes per ng DNA of left and right ventricular myocardium.
Histologic analysis
To characterize spatial distribution of gene transfer with UTMD, we analyzed rats that were subjected to gene delivery with AAV-9 vectors encoding an enhanced green fluorescent protein (EGFP) reporter gene either with or without microbubbles in the presence of ultrasound. Although only few green fluorescent cells could be detected in control animals (having received virus and ultrasound without microbubbles), EGFPpositive cells could be detected all over the myocardium, especially in the anterior wall of the left ventricle after UTMD treatment ( Figure 4 ).
Hematoxylin/eosin (HE) staining of sections from hearts subjected to UTMD revealed no signs of tissue destruction, fibrosis or round cell infiltration as shown on representative sections ( Figure 5 ).
Echocardiography
To rule out changes in cardiac function echocardiography was performed in treated and untreated rats. Echocardiographic analysis of left ventricular function did not show any difference between both groups (fractional shortening: treated rats 68.2±0.6% vs controls 70.3 ± 3.9%; P ¼ 0.4).
Discussion
AAV vectors are considered as promising tools for cardiac gene therapy. Although even systemic application is feasible for cardiac transduction in mice, much Augmentation of cardiac AAV gene transfer OJ Müller et al higher total counts of vector particles would be needed in larger animals, if noninvasive application is intended. Therefore, the aim of this study was to test whether the combination of optimized AAV vectors with UTMD would allow for sufficient cardiac transgene expression in rats. We also addressed the question whether administration of AAV-9-pseudotyped vectors could lead to a more efficient gene expression in rats than AAV-6 when using UTMD. With respect to potential therapeutic applications, we finally investigated, whether UTMDenhanced AAV delivery to the myocardium causes relevant adverse effects.
UTMD has previously been used to efficiently deliver adenoviral vectors 33 and plasmid DNA [34] [35] [36] to the heart. In contrast to the transient expression mediated by those vector systems, AAV vectors enable long-term gene expression in the heart of small and large animals. 5, 16, 24, 37 Our study demonstrates that UTMD loaded with AAV-6 or -9 significantly increased cardiac reporter gene expression compared to systemic infusion of vectors without microbubbles in the presence of ultrasound. As the diagnostic ultrasound used in this study is not able to increase transduction itself, 34 the increased transduction efficiency in the microbubble group can be explained by high local vector concentration after destruction of AAV-loaded microbubbles in the cardiac capillaries and increased capillary permeability resulting from high velocity fluid microjets. 32 The high hepatic transduction levels with AAV-6 vectors might be a species effect, as their regulatory sequence previously showed predominantly cardiac transgene expression after intravenous bolus injection of an AAV-6 vector into mice. 25 The sustained intravenous infusion of a low amount of vector could also result in a different dose/transduction effect in distinct tissues as shown before. 26 Nevertheless, destroying microbubbles in the heart can still inverse cardiac to hepatic transduction ratios, thus increasing organ specificity for the heart.
Comparing transduction efficiency and specificity of different AAV serotype vectors by intravenous bolus injection in mice showed that AAV-6, -8 and -9 serotype vectors resulted in uniform and extensive cardiac gene transfer. [24] [25] [26] [27] [28] The efficient gene transfer by a systemic transvascular route can be attributed to the ability of certain AAV serotypes to easily cross the blood vessel barrier in rodents. Furthermore, efficient spreading through the extracellular matrix, as previously shown for AAV-6 and -8, may additionally contribute to the increased transduction. Limited spreading of AAV-2 through the extracellular matrix may also explain why UTMD loaded with AAV-2 did not result in significant reporter activities despite of the facilitated endothelial penetration by UTMD (data not shown). In contrast, UTMD additionally increased cardiac transduction of AAV-6 and -9 vectors by increased local concentrations and facilitated endothelial passage as discussed above. Although AAV-9 enabled the most efficient gene transfer after intravenous injection in mice, 27, 28 our study showed no significant difference in transgene expression between AAV-6 or -9 vectors, both in the microbubble and control groups. This might be explained by species differences.
Spatial detection of cardiac gene transfer using EGFPencoding vectors revealed green fluorescent cells predominantly in the anterior wall within the microbubble group, whereas almost no signal was detectable in hearts when UTMD was not applied. This localized expression pattern is in accordance to previously described studies. 34, 35 It has been speculated that attenuation of ultrasound due to the high microbubble concentration in the ventricular cavity may decrease the ultrasound energy at the posterior wall. In future clinical applications, this phenomenon could be overcome by an additional transesophageal ultrasound application.
Ultrasound-targeted microbubble destruction may cause adverse effects in the heart, inducing hemorrhages and arrhythmia. [38] [39] [40] [41] However, clinically irrelevant conditions were mostly used in these studies, such as extremely high doses of microbubbles, continuous high energy ultrasound exposure, open chest ultrasound exposure or ex vivo sonication of hearts. Using similar parameters as described in our experiments, other studies have demonstrated no relevant cardiac adverse events. 42, 43 Nevertheless, it was important for this novel combination of UTMD-mediated cardiac AAV delivery to rule out relevant damage or inflammation to the myocardium. Histological analysis showed no cell infiltration or tissue damage. Functional analysis of hearts, using echocardiography, demonstrated no significant differences between UTMD and virus-treated rats versus -untreated control rats. Thus, we can assume that this technique is safe. Before using this tool in clinical studies, safety analysis has to be performed in large animal models.
In summary, our study shows for the first time the potential of UTMD to target AAV vectors into rat hearts. Of note, this is a noninvasive technique that can be applied by intravenous, systemic administration of the vector, in contrast to direct intramyocardial or intracoronary injection. Using the combination of AAV-loaded microbubbles and ultrasound, it is possible to downscale the amount of virus. Considering the degree of augmentation in the anterior wall and our experience with systemic gene transfer in mice (that are 10 times smaller than rats) using the same amount of these viral constructs, we assume that we can save at least one order of magnitude of virus, when using microbubbles. Further improvement in microbubble composition and three dimensional ultrasound applications may even further increase this effect. Thus, it may offer the possibility to use systemic administration of AAV vectors even in humans, without the necessity to use unrealistically high doses of viral particles. However, further work is essential to transfer this approach to a larger animal model and to use functional/therapeutic genes that would cause a physiologic response. 
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Methods
Generation of AAV vectors
AAV vectors were produced and purified using standard procedures. 25, 44 Purification was achieved by filtration cascade (first 5 mm, second 0.8 mm, third 0.2 mm) and iodixanol step gradient centrifugation, as previously described.
25
For AAV-2-and AAV-6-pseudotyped vectors, the helper plasmids pDP2 or pDP6 were co-transfected with pUFCMV enh /MLC1.5-Luc containing AAV-9-pseudotyped vectors were generated by triple transfection of p5E18-VD2-9, 45 providing the AAV-9 capsid sequence, and pDGdelVP, 25 containing the AAV-2 reporter gene as well as adenoviral helper sequences, together with either pUFCMV enh /MLC1.5-Luc 25 or pdsCMV-MLC0. 26-EGFP. pdsCMV-MLC0.26-EGFP provides a self-complementary vector genome, in which the CMV promoter of pdsCMV-GFP was replaced by a MluI/HindIII fragment of the CMV-enhanced 260 bp myosin light chain-2v promoter from pUFCMV-MLC0.26-Luc, a derivate of pUFCMV-MLC1.5-Luc lacking the 5 0 -upstream myosin light-chain regulatory sequence between the CMV enhancer and the 3 0 -PpuMI restriction site.
Microbubbles AAV-loaded microbubbles were produced by a modification of a previously described method. 34 Solution (1frac12 ml) containing 4 Â 10 10 genomic particles AAV-6 or -9, 1% DL-a-phosphatidylcholine (Sigma, Munich, Germany), 0.25% DL-a-phosphatidylethanolamine (Sigma) and 10% glycerol in phosphate-buffered saline (PBS) was incubated at 20 1C for 10 min. It was then transferred to a tube filled with octafluoropropanegas and shaken for 20 s at 4300 oscillations per minute (Capmix, 3 M, St Paul, MN, USA). This solution was then diluted with 0.5 ml of PBS prior to injection.
Microbubble size and concentration were measured prior to injection (Multisizer 3, Beckman Coulter, FL, USA).
Immunostaining of microbubbles containing AAV vectors
As the described lipid components would result in anionic microbubbles (at physiologic pH) and the AAV surface is cationic, it was hypothesized that AAV particles would bind on the microbubble surface. To test this, we produced AAV-2-loaded microbubbles with a higher AAV/microbubble ratio. Similar to the protocol stated above, we generated microbubbles using 50 ml of lipid suspension with 4 Â 10 10 genomic particles AAV-2 and a second group without AAV. These were washed by floatation for 30 min in 1 ml PBS and by removal of the subnatant. Microbubbles were then incubated with A20 (1:100), a monoclonal antibody against intact AAV-2 46 for 30 min during gentle shaking. Microbubbles were washed three times as described above and then incubated with a secondary, cy3-labeled rabbit-anti-mouse antibody (1:500). Microbubbles were again washed three times, and AAV binding was analyzed using a fluorescence microscope (Leica, Bensheim, Germany).
In vivo gene transfer
All procedures were approved by the local animal care committee. A total of 34 Sprague-Dawley rats (200-250 g) were used for our experiments.
Rats were anesthetized with an intraperitoneal injection of 400 mg kg À1 2,2,2-tribromethanol (Sigma). A polyethylene tube was inserted into the right internal jugular vein. After shaving and depilating the chest, the transducer was placed on the thorax in a mid-short axis view with a 1.5 cm gel standoff. The microbubble (1 ml) suspension or pure virus suspension was infused at a constant rate of 3 ml h À1 for 20 min. Microbubble destruction was obtained using a Sonos 5500 machine (Philips, Eindhoven, the Netherlands) with an S3 transducer operating in ultraharmonic mode (transmit 1.3 MHz) at a mechanical index of 1.6 (corresponds to a peak negative pressure of about 1.8 MPa at a depth of 2 cm). Sonography was ECG triggered, at 80 ms after the peak of the R-wave, to deliver a burst of four frames of ultrasound (with four cycles per frame) every four cardiac beats. At the end of the experiment the jugular vein was tied off and the skin closed. After 4 weeks, animals were euthanized and various organs (heart, skeletal muscle, lung, liver, spleen and kidney) were harvested and frozen in liquid nitrogen for later luciferase assays. Hearts were dissected into atria, left and right ventricles. Animals having received the EGFP vector were euthanized, and dissected organs were fixed for 4 h at 4 1C in PBS containing 0.1%glutaraldehyde/ 1.5% paraformaldehyde/20% sucrose, embedded in Tissue Freezing Medium (Leica, Bensheim, Germany) and slowly frozen to À20 1C. For HE staining, rats were euthanized, perfused in vivo with PBS and 4% formaldehyde at 37 1C, dissected and fixed in 4% buffered formaldehyde overnight at 4 1C. The whole heart was then embedded in Paraplast (Roth, Karlsruhe, Germany) at 60 1C and 10 mm sections were cut.
Various protocols were applied to test the effect of UTMD on cardiac transduction. Using luciferase-encoding AAV-6, six rats received microbubbles loaded with 4 Â 10 10 genomic particles and ultrasound to the heart, and six rats received 4 Â 10 10 genomic particles in PBS (without microbubbles) and ultrasound to the heart (two died before harvesting).
Using luciferase-encoding AAV-9, four rats received microbubbles loaded with 4 Â 10 10 genomic particles and ultrasound to the heart and four rats received 4 Â 10 10 genomic particles in PBS (without microbubbles) and ultrasound to the heart. Using GFP-encoding AAV-9, four rats received microbubbles loaded with 1 Â 10 11 genomic particles and ultrasound to the heart and four rats received 1 Â 10 11 genomic particles in PBS and ultrasound to the heart. Finally, for HE staining, two rats received microbubbles loaded with 1 Â 10 11 genomic particles (encoding luciferase) and ultrasound to the heart, two rats received PBS (without microbubbles) and two rats received microbubbles loaded with 4 Â 10 10 genomic particles without ultrasound.
Measurement of luciferase activities
Frozen tissue samples were homogenized in reporter lysis buffer (Promega, Mannheim, Germany) and centrifuged for 10 min at 10 000 g. The supernatant was used to determine luciferase reporter activities with a commercial luciferase assay kit (Promega) in a luminometer (Lumat LB9501; Berthold, Bad Wildbad, Germany). Protein concentration in tissue homogenates was determined with the NanoOrange Kit (Molecular Probes, Leiden, the Netherlands). Luciferase activities are expressed in relative light units per mg protein.
Vector genome quantification
Genomic DNA was extracted from heart and liver tissue using the DNeasy tissue kit (Qiagen, Hilden, Germany).
Augmentation of cardiac AAV gene transfer OJ Müller et al Viral DNA was quantified using TaqMan quantitative real-time PCR (QR-PCR) using the primer/probe set TGCCCAGTACATGACCTTATGG (forward)/GAAATC CCCGTGAGTCAAACC (reverse); 6-fam-AGTCATCGC TATTACCATGG-MGB. Extracted DNA (15-50 ng) was applied for QR-PCR under the conditions previously described. 47 Products were evaluated with TaqMan data analysis software (Applied Biosystems, Darmstadt, Germany).
Histological analysis
To determine transduction efficiency, we performed 10 mm cryosections of the hearts that were evaluated for EGFP expression by fluorescence microscopy (Nikon Eclipse 90i upright automated microscope, Dü sseldorf, Germany) using a D1QM camera (Nikon, Dü sseldorf). Optical overview images were obtained by the scan large image function of the microscope. Representative sections of the large image were further enlarged and evaluated with 515-555 and 605-655 nm after Alexa Fluor 546-phalloidin staining. Both channels were merged afterward.
Single cell evaluations were performed by confocal microscopy (Nikon C1Si spectral imaging confocal laser scanning system, Dü sseldorf, Germany). The Argon ion lasers (405, 488 of 514 and 561 nm) with filter settings (450/35, 515/30, 605/75) for 46-diamidino-2-phenyl indole/fluorescein isothiocyanate/Alexa Fluor 546 fluorescence were used for detection. Representative sections were enlarged with an average of four and all three channels have been merged afterward.
To rule out relevant inflammation, 10 mm sections were deparaffinized in xylene, rehydrated in a descending series of ethanol, stained with hematoxylin/ eosin and embedded in Eukitt (Roth, Karlsruhe, Germany). The tissue was evaluated by transmission microscopy (Nikon Eclipse 90i upright automated microscope, Dü sseldorf, Germany) using the DXM-1200C color-camera.
Echocardiography
To test for UTMD-related adverse effects to hearts, we performed diagnostic echocardiography. At 4 weeks after transfection, three rats that had been treated with luciferase-encoding AAV-6 and UTMD were compared with three untreated control rats. Echocardiography was performed using a Sonos 5500 (Philips, Eindhoven) with a S12 transducer (12 MHz). The echocardiographer was blinded with respect to the treatment group. To avoid anesthetic-related impairment of cardiac function during echocardiography, 48 examinations were performed on lightly sedated animals using an intraperitoneal injection of 100 mg kg À1 2,2,2-tribromethanol (Sigma). Left ventricular parasternal short-axis views were obtained in M-mode imaging at the papillary muscle level. An M-mode image was stored digitally. The blinded echocardiographer analyzed the stored images at a later time point. Three consecutive beats were used for measurements of left ventricular end-diastolic internal diameter (LVEDD) and left ventricular end-systolic internal diameter (LVESD) according to the American Society of Echocardiography leading edge method. 49 Fractional shortening (FS) was calculated as FS% ¼ ((LVEDDÀLVESD)/LVEDD) Â 100.
Statistical analyses
All data were expressed as mean±standard error. To test for statistical significance either an unpaired Student's t-test or, if several groups were compared, analysis of variance for multiple group comparisons were applied.
